Sign in to our online system or register for a new account to submit a letter of intent.
*The deadline for submitting applications to our Netherlands: Rapid Response 2016 program has now passed.
The prevalence of neurodegenerative diseases of aging is high and growing rapidly. The Netherlands: Rapid Response 2016 program was created to jumpstart the development of safe and effective treatments for these diseases. The program provides seed funding for novel, high-risk, high-reward patient-oriented translational research projects in the Netherlands. Proposed projects may relate to any disease; however, the basis for selection will be on the potential impact of the project on neurodegenerative diseases of aging.
Projects can request up to €120,000 over up to 18 months.
Principal Applicant must be either a researcher at or above the level of Universitair Docent (or equivalent) or a researcher at or above the level of Post-doctoral Fellow with an Administrative Supervisor at a Public Benefit Organisation in the Netherlands.
The Rapid Response Netherlands 2016 program funds patient-oriented translational research.
Projects must meet two conditions to be eligible:
Among other things, this call excludes:
Program Information Sessions: Thursday, December 17th, 2015, 16:00 CET and Wednesday, January 13th, 2016, 16:00 CET (further details can be found below)
Letter of Intent (LOI) Deadline: Tuesday, February 2nd, 2016, 16:00 CET
Proposal Invitations: March 2016
Proposal Deadline: Tuesday, May 3rd, 2016, 16:00 CET
Anticipated Award Notification: June 2016
*Dates may change
There are two stages to the application process: Letter of Intent (LOI) and Proposal stage. An application requires the submission of a Letter of Intent which will be reviewed by our Scientific Review Committee. Applicants with high potential projects will be invited to submit a Proposal; instructions will be forwarded along with the invitation in June, 2016.
Please refer to our Program Details for more information on this opportunity.
The Program Information Sessions being held on Thursday, December 17th, 2015, 16:00 CET and Wednesday, January 13th, 2016, 16:00 CET will provide further details on the program and application process and an opportunity to ask questions.
Neurodegenerative disease of aging: As the Institute defines them, neurodegenerative diseases of aging are diseases that primarily affect the structure and/or function of brain neurons where the average age of onset is 50 or older. The Institute considers the following as neurodegenerative diseases of aging: Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Lewy body dementia, frontotemporal dementia, multiple system atrophy, Parkinson’s disease, progressive supranuclear palsy, vascular contributions to neurodegeneration (not stroke-mediated vascular disease), and prodromes to the listed diseases [e.g., mild cognitive impairment as prodromal to Alzheimer’s disease; cognitive impairment in Down syndrome as a prodrome to Alzheimer’s disease (but not Down syndrome as relevant to general cognitive issues); REM sleep behavior disorder as prodromal to Parkinson’s disease].
Translational Research: Applied research towards developing therapeutics for the prevention and/or treatment of human disease. For example, for small molecule drug development, this includes target validation to Phase II clinical trials.
Therapeutics: A pharmacological approach (including small molecules, biologics, cell therapies and vaccines, including drug repositioning and repurposing), medical device, surgical intervention, magnetic or electrical brain stimulation, but not complementary approaches such as exercise, acupuncture, foods, or dietary or nutritional supplements. Therapeutics can be for symptomatic relief, disease modification, or prevention.
The Institute welcomes inquiries about this request for applications or any of our other funding opportunities. We would be pleased to hear from you at either email@example.com or +1 416-935-4056.
Information on past Canadian iterations of the Rapid Response Program can be found here.